{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:51:19Z","timestamp":1791341479225,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.vaccine.2011.01.102","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T15:14:12Z","timestamp":1297782852000},"page":"2777-2784","source":"Crossref","is-referenced-by-count":92,"title":["A novel broad-spectrum treatment for respiratory virus infections: Influenza-based defective interfering virus provides protection against pneumovirus infection in vivo"],"prefix":"10.1016","volume":"29","author":[{"given":"Andrew J.","family":"Easton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Edworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel J.","family":"Dimmock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.01.102_bib0005","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1128\/JVI.00743-08","article-title":"Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral","volume":"82","author":"Dimmock","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0010","series-title":"Fields virology","first-page":"1353","article-title":"Orthomyxoviridae: the viruses and their replication","author":"Lamb","year":"1996"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0015","series-title":"Fields virology","first-page":"1177","article-title":"Paramyxoviridae: the viruses and their replication","author":"Lamb","year":"1996"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0020","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3201\/eid1411.080958","article-title":"Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa","volume":"14","author":"Besselaar","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0035","series-title":"Virology","first-page":"77","article-title":"Generation and replication of defective viral genomes","author":"Holland","year":"1990"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/226325a0","article-title":"Defective viral particles and viral disease processes","volume":"226","author":"Huang","year":"1970","journal-title":"Nature (Lond)"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-642-68123-3_7","article-title":"Origin and replication of defective interfering particles","volume":"93","author":"Perrault","year":"1981","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0050","series-title":"The influenza viruses","first-page":"269","article-title":"Structure of defective-interfering RNAs of influenza virus and their role in interference","author":"Nayak","year":"1989"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0055","series-title":"Virology","first-page":"151","article-title":"Defective viral genomes","author":"Holland","year":"1990"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0065-3527(08)60529-1","article-title":"Incomplete forms of influenza virus","volume":"21","author":"von Magnus","year":"1954","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0065","first-page":"1","article-title":"Studies on interference in experimental influenza. I. Biological observations","volume":"24b","author":"von Magnus","year":"1947","journal-title":"Ark Kemi Mineral Geol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0070","first-page":"1","article-title":"Studies on interference in experimental influenza. II. Purification and centrifugation experiments","volume":"24b","author":"Gard","year":"1947","journal-title":"Ark Kemi Mineral Geol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.mi.34.100180.003155","article-title":"Influenza virus defective interfering particles","volume":"34","author":"Nayak","year":"1980","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-642-70227-3_3","article-title":"Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression and interference","volume":"114","author":"Nayak","year":"1985","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0092-8674(83)90394-X","article-title":"Does the higher order of the influenza virus ribonucleoprotein guide sequence rearrangements in influenza viral RNA","volume":"34","author":"Jennings","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/viro.1998.9267","article-title":"Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung","volume":"248","author":"Duhaut","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/viro.2000.0502","article-title":"Approximately 150 nt from the 5\u2032 end of an influenza A virus segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells","volume":"275","author":"Duhaut","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1099\/0022-1317-83-2-403","article-title":"Defective segment 1 RNAs that interfere with the production of infectious influenza virus require at least 150 nucleotides of 5\u2032 sequence: evidence from a plasmid-driven system","volume":"83","author":"Duhaut","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0166-0934(02)00260-4","article-title":"Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease","volume":"108","author":"Duhaut","year":"2003","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/rmv.641","article-title":"Defective interfering viruses and their potential as antiviral agents","volume":"20","author":"Marriott","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-3527(08)60279-1","article-title":"Effects of defective interfering viruses on viral replication and pathogenesis in vitro and in vivo","volume":"40","author":"Roux","year":"1991","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0120","series-title":"Viral and other infections of the respiratory tract","first-page":"421","article-title":"Antiviral activity of defective interfering influenza virus in vivo","author":"Dimmock","year":"1996"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/rmv.1980010306","article-title":"The biological significance of defective interfering viruses","volume":"1","author":"Dimmock","year":"1991","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-71272-2_2","article-title":"Defective interfering viruses and infections of animals","volume":"128","author":"Barrett","year":"1986","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0042-6822(89)90637-5","article-title":"Interferon induction by viruses. XIX. Vesicular stomatitis virus-New Jersey: high multiplicity passages generate interferon-inducing, defective-interfering particles","volume":"171","author":"Marcus","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0140","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/266815a0","article-title":"Defective interfering particles with covalently linked +RNA induce interferon","volume":"266","author":"Marcus","year":"1977","journal-title":"Nature (Lond)"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0042-6822(82)90530-X","article-title":"Interferon induction by viruses. VIII. Vesicular stomatitis virus: [+\/\u2212] DI-011 particles induce interferon in the absence of standard virions","volume":"117","author":"Sekellick","year":"1982","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virol.2006.03.022","article-title":"Sendai defective-interfering genomes and the activation of interferon-beta","volume":"351","author":"Strahle","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0042-6822(79)90040-0","article-title":"Induction of interference in L cells by defective-interfering (DI) particles of vesicular stomatitis virus: lack of correlation with content of [+\/\u2212] snapback RNA","volume":"99","author":"Frey","year":"1979","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0160","doi-asserted-by":"crossref","first-page":"16303","DOI":"10.1073\/pnas.1005077107","article-title":"Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing","volume":"107","author":"Baum","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/CMR.17.2.390-412.2004","article-title":"Animal pneumoviruses: molecular genetics and pathogenesis","volume":"17","author":"Easton","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0170","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/0022-1317-67-6-975","article-title":"Murine pneumonia virus: seroepidemiological evidence of widespread human infection","volume":"67","author":"Pringle","year":"1986","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0175","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1099\/0022-1317-75-12-3485","article-title":"Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus","volume":"75","author":"Noble","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0180","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.vaccine.2004.02.013","article-title":"Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing","volume":"22","author":"Noble","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0185","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1099\/0022-1317-79-10-2411","article-title":"Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization","volume":"79","author":"Cook","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0190","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1128\/JVI.68.8.5330-5334.1994","article-title":"Sequence of the phosphoprotein gene of pneumonia virus of mice: expression of multiple proteins from two overlapping reading frames","volume":"68","author":"Barr","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0195","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bbrc.2007.02.019","article-title":"Protection from lethal influenza virus challenge by oral type 1 interferon","volume":"355","author":"Beilharz","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0200","doi-asserted-by":"crossref","first-page":"10818","DOI":"10.1128\/JVI.01116-07","article-title":"The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses","volume":"81","author":"Tumpey","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0205","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/JVI.02453-08","article-title":"Intranasal administration of \u03b1 interferon reduces seasonal influenza A virus morbidity in ferrets","volume":"83","author":"Kugel","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0210","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1016\/j.vaccine.2010.03.062","article-title":"A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits","volume":"28","author":"Gao","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0215","first-page":"6902","article-title":"Viruses and interferon: a fight for supremacy","volume":"419","author":"Katze","year":"2002","journal-title":"Nature (Lond)"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0220","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2011.01.102_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J Gen Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T14:58:56Z","timestamp":1592319536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0264410X11001745"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.01.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}